Scaffolds fabricated from electrospun decellularized extracellular matrix

Patent metadata

Field	Value
Publication number	US-2023158208-A1
Application number	US-202318100000-A
Country	US
Kind code	A1
Filing date	Jan 23, 2023
Priority date	Apr 12, 2016
Publication date	May 25, 2023
Grant date	—

Abstract

A scaffold comprising electrospun decellularized ECM of an organ, wherein the decellularized ECM has a similar protein composition to native ECM of the organ. Methods of generating same are also disclosed as well as uses of same.

First claim

What is claimed is:

1 . A method of generating a scaffold comprising:
(a) homogenizing decellularized extracellular matrix (ECM) in an organic solvent using a bead homogenizer to generate a homogenate of decellularized ECM; (b) electrospinning said homogenate onto a solid surface thereby generating the scaffold.

2 . The method of claim 1 , wherein said ECM is not derived from fat tissue.

3 . The method of claim 1 , wherein said ECM is derived from an organ selected from the group consisting of heart and pancreas.

4 . The method of claim 1 , further comprising decellularizing a tissue of a subject to generate said decellularized ECM prior to step (a).

5 . The method of claim 1 , wherein said homogenizing is effected at 6000 rpm.

6 . The method of claim 1 , wherein said organic solvent is selected from the group consisting of acetone, N,N-dimethylformamide (DMF), diethylformamide, chloroform, methylethylketone, acetic acid, formic acid, ethanol, 1,1,1,3,3,3-hexa fluoro-2-propanol (HFIP), tetrafluoroethanol, dichloromethane (DCM), tetrahydrofuran (THF), trifluoroacetic acid (TFA), camphorsulfonic acid, dimethyl acetamide, isopropyl alcohol (IPA) and mixtures thereof.

7 . The method of claim 1 , wherein said organic solvent is HFIP.

8 . The method of claim 1 , further comprising contacting said homogenate of decellularized ECM with a polymer so as to increase the viscoelasticity of said homogenate following step (a) and prior to step (b).

9 . The method of claim 8 , wherein said synthetic polymer is selected from the group consisting of poly(D,L-lactide) (PLA), poly(urethanes), poly(siloxanes), poly(silicones), poly(ethylene), poly(vinyl pyrrolidone), poly(2-hydroxy ethyl methacrylate), poly(N-vinyl pyrrolidone), poly(methyl methacrylate), poly(vinyl alcohol) (PVA), poly(acrylic acid), poly(vinyl acetate), polyacrylamide, poly(ethylene-co-vinyl acetate), poly(ethylene glycol), poly(methacrylic acid), polyglycolic acids (PGA), poly(lactide-co-glycolides) (PLGA), nylons, polyamides, polyanhydrides, poly(ethylene-co-vinyl alcohol) (EVOH), polycaprolactone, poly(vinyl acetate), polyvinylhydroxide, poly(ethylene oxide) (PEO), polyorthoesters and mixtures thereof.

10 . The method of claim 8 , wherein said polymer is PEO.

11 . The method of claim 10 , wherein the amount of said PEO in said homogenate is between 0.05-1% mass.

12 . The method of claim 8 , further comprising removing said polymer following said electrospinning.

13 . The method of claim 1 , further comprising sonicating said homogenate following step (a) and prior to step (b).

14 . The method of claim 1 , further comprising mixing said homogenate by placing on a rotator for at least 1 day prior to step (b).

15 . The method of claim 1 , further comprising filtering said homogenate of decellularized ECM prior to said electrospinning.

16 . A scaffold generated according to the method of claim 1 .

17 . A method of treating a medical condition which may benefit from cell transplantation or regenerative therapy in a subject in need thereof, the method comprising transplanting the scaffold of claim 16 into the subject, thereby treating the medical condition.

Assignees

• Technion Res & Dev Foundation

Inventors

• Machluf Marcelle
• Zussman Eyal
• Baruch Limor

Classifications

• A61L27/3633

  Extracellular matrix [ECM] · CPC title

• A61L27/3804 Primary

  characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K35/28

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title